Why the study?
Lymphoma confers a high risk of VTE, but risk factors appear to differ from those in solid tumors.
Population
Cohorts consisting exclusively of lymphoma patients across 25 selected publications
Design
Literature review of 25 publications from the last 20 years
Authors
Loading...
Should not yet change VTE prophylaxis practice in lymphoma; leaves open prospective validation of risk-adapted strategies.
VTE risk in lymphoma is highest in the first two months and is driven by aggressive histology, poor performance status, and extensive disease, highlighting the need for validated risk scores to guide primary prophylaxis.
Hohaus et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: